MGX vs. INBX, HUMA, PRME, MESO, PROK, SRRK, TSHA, RGNX, CRGX, and HLVX
Should you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Inhibrx (INBX), Humacyte (HUMA), Prime Medicine (PRME), Mesoblast (MESO), ProKidney (PROK), Scholar Rock (SRRK), Taysha Gene Therapies (TSHA), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), and HilleVax (HLVX). These companies are all part of the "biological products, except diagnostic" industry.
Inhibrx (NASDAQ:INBX) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.
Metagenomi has higher revenue and earnings than Inhibrx.
In the previous week, Inhibrx had 14 more articles in the media than Metagenomi. MarketBeat recorded 14 mentions for Inhibrx and 0 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.05 beat Inhibrx's score of 0.00 indicating that Inhibrx is being referred to more favorably in the media.
Inhibrx received 22 more outperform votes than Metagenomi when rated by MarketBeat users. However, 90.00% of users gave Metagenomi an outperform vote while only 60.78% of users gave Inhibrx an outperform vote.
Metagenomi has a net margin of 0.00% compared to Metagenomi's net margin of -13,408.95%. Inhibrx's return on equity of 0.00% beat Metagenomi's return on equity.
82.5% of Inhibrx shares are held by institutional investors. 22.2% of Inhibrx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Inhibrx presently has a consensus price target of $27.00, indicating a potential upside of 62.16%. Metagenomi has a consensus price target of $17.83, indicating a potential upside of 193.31%. Given Inhibrx's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Inhibrx.
Summary
Metagenomi beats Inhibrx on 9 of the 15 factors compared between the two stocks.
Get Metagenomi News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Metagenomi Competitors List
Related Companies and Tools
